NCT00501332 - Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2007

Conditions

Chemotherapy-Induced NeutropeniaBreast Cancer

Interventions

BIOLOGICAL

Maxy-G34

Maxy-G34 will be administered by subcutaneous injection during each of 6 TAC chemotherapy cycles.

Trial Locations (15)

RECRUITING

Bydgoszcz

RECRUITING

Gdansk

RECRUITING

Lublin

ACTIVE_NOT_RECRUITING

Alba Iulia

ACTIVE_NOT_RECRUITING

Bucharest

RECRUITING

Jud. Bacau

RECRUITING

Suceava

RECRUITING

Timișoara

ACTIVE_NOT_RECRUITING

Leningrad Region

ACTIVE_NOT_RECRUITING

Moscow

RECRUITING

Moscow Area

ACTIVE_NOT_RECRUITING

Ryazan

ACTIVE_NOT_RECRUITING

Saint Petersburg

RECRUITING

Dnipropetrovsk

RECRUITING

Uzhhorod